Abstract Guideline

Paper Submission Guidelines

• Prior Publication: An abstract is not eligible for submission if it has been presented at another national or international meeting or will be published prior to the 14th International Congress of Endocrine Disorders, November 22-24, 2023. Failure to notify the scientific committee of such publication or presentation will result in a moratorium on the submission of abstracts for all the authors in question for one year.

• Authorship Requirements: There is no limit to the number of abstracts an author may submit.

Author`s name: The author list should include each author`s first initial and complete last name with the presenter identified by underline. The affiliations should be annotated as shown below.

 Example: F

 Ramezani Tehrani1, N Moslehi2, G Asghari2, R Gholami1, P Mirmiran3, F Azizi4.

1- Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2-…

 Disclosure Information: This information is required of all authors for each submitted abstract and is to be included at the end of abstract (not included in character count). It is the responsibility of the abstract submitter to ensure that the disclosure information of all authors is entered accurately into the abstract submission site.

Unless authors have specific disclosures to state (for example industrial affiliations, etc ), they should enter the phrase: Nothing to disclose.

 Character Count & Writing Standards

The format of an abstract should contain: Title, Author`s name, Abstract body, Disclosure.

The abstract must be prepared with Times New Roman, font12.

 • Character Count: Abstracts are limited to 400 words, not including spaces. The abstract title (Bold) and body count toward the character limit.

 • Abstract Body: Make abstracts as informative as possible, including a brief statement of the purpose of the study or why it was done, the methods used, the results observed, and the author(s)` conclusions based upon the results. Actual data should be summarized. It is inadequate to state "the results will be discussed" or "the data will be presented." Abstracts must be written in English.

- Do NOT use subtitles (e.g., Methods, Results) in the abstract body.

- Do NOT include grant support information in the abstract body.

- Do NOT enter author, title, or grant information into the “Abstract Body” text box.

- The use of standard abbreviations is requested. Examples include: kg, g, mg, ml, L (liter), mEq (milliequivalent), m (meter), mmol/L (millimoles per liter), / (per), and % (percent).

- Place a special or unusual abbreviation in parentheses after the full word the first time it appears, and then use the abbreviation throughout the remainder of the abstract.

- Use numerals to indicate numbers, except when beginning sentences.

- Nonproprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters, followed by the trade name in parentheses. Trade names are always capitalized. Example: aspirin (Bufferin).

- When discussing therapeutic options, it is our preference that you use only generic names. If it is necessary to use a trade name, then those of several companies must be used. In addition, should your presentation include discussion of any unlabeled or investigational use of a commercial product, you are required to disclose this at the time of presentation.

The format of an abstract should be as below:
Author`s name:
Abstract body:

The authors will bear full responsibility for the accuracy of their English abstracts